News
There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...
One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an ...
Three of the health secretary’s picks to replace fired members of an influential panel that sets U.S. vaccine policies have ...
Two new vaccine advisers tapped by Health and Human Services Secretary Robert F. Kennedy Jr. have served as paid expert ...
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
5don MSN
Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...
Shares of pharmaceutical company Merck (NYSE: MRK) were recently down about 40% over the past year, partly due to concerns ...
Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.
Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
Citizens Financial Group (CFG) will be expanding its share buyback program to $1.5 billion. Pharmaceutical giant Merck (MRK) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results